- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- CT – 0508OpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
Carisma Therapeutics is building a pipeline with an initial focus in oncology aiming to bring the power of cellular immunotherapy to the large number of solid tumor patients, in whom other approaches fail. At the start of 2021, Carisma initiated the first ever clinical study of a CAR-Macrophage therapy for patients, achieving a key milestone in the development of this new therapeutic approach, and giving hope to patients living with cancer.
| Current Portfolio | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
CT – 0508 (CAR-Macrophage)Discovery | Preclinical | Phase 1 |
|||
CT – 0508 + Pembro (CAR-Macrophage)Discovery | Preclinical | Phase 1 |
|||
CT – 0525 (CAR-Monoctye)Discovery | Preclinical | Phase 1 |
|||
CT – 1119 (Mesothelin)Discovery | Preclinical | Phase 1 |
|||
CT – 0729 (PSMA)Discovery | Preclinical | Phase 1 |
|||
In-Vivo mRNA CAR-MDiscovery | Preclinical | Phase 1 |
Carisma is developing CT-0508, an ex vivo gene-modified autologous CAR-Macrophage cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. CT-0508 is in Phase 1 clinical development.
Carisma has initiated a clinical study for CT-0508 in combination with Pembrolizumab. The goal of this study is to assess the potential synergy between CAR-Macrophages and anti-PD1 therapy to deliver additional benefit to patients.
Carisma is developing CT-0525, an ex vivo gene-modified autologous CAR-Monocyte cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. CT-0525 is in pre-clinical development.
Carisma is developing CT-1119, an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to target mesothelin-positive solid tumors. CT-1119 is in pre-clinical development.
Carisma is developing CT-0729, an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to target prostate-specific membrane antigen for treatment of metastatic castration-resistant prostate cancer. CT-0729 is in discovery.
Carisma is partnering with Moderna Therapeutics to develop the next generation of macrophage-targeted in-vivo therapies to address multiple cancer targets.
Carisma’s scientists are expanding the functionality of engineered macrophages to increase the number of patients that can potentially benefit from this transformative technology. With research programs targeting neurodegeneration, liver fibrosis and autoimmune disorders Carisma is pushing the boundaries of what is possible.
We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.
| R & D Engine | Discovery | Preclinical | Phase 1 |
|---|---|---|---|
NeurodegenerationDiscovery | Preclinical | Phase 1 |
|||
Liver fibrosisDiscovery | Preclinical | Phase 1 |
|||
Autoimmune diseasesDiscovery | Preclinical | Phase 1 |
If there are important updates to our pipeline or research, you can be the first to hear about them.
Read the latest news, announcements, and more in the Carisma Therapeutics newsroom.
We have decades of experience in the industry, and are working to a develop a new approach to cell therapies.
Get to know the team committed to developing innovative treatments for patients.
Our Team